Posts tagged medicine
Articles and news from the latest research reports.
Worm Regeneration May Lend A Hand in Human Healing
About the size of toenail clippings, planarians are freshwater flatworms that can re-form from tiny slivers. This feature not only lets them repair themselves, but it lets them reproduce by breaking apart and then creating new worms.
Here are two other important features: More than half of planarian genes have parallels in people, and some of their basic physiological systems operate like ours. By studying how these features behave as the worms regenerate, scientists might move one step closer to learning how to generate or regenerate human tissue and cells, such as insulin-producing cells for people with diabetes or nerve cells for patients with spinal cord injuries.
For brain tumors, origins matter
Cancers arise when a normal cell acquires a mutation in a gene that regulates cellular growth or survival. But the particular cell this mutation happens in—the cell of origin—can have an enormous impact on the behavior of the tumor, and on the strategies used to treat it.
Robert Wechsler-Reya, Ph.D., professor and director of the Tumor Development Program in Sanford-Burnham’s NCI-designated Cancer Center, and his team study medulloblastoma, the most common malignant brain cancer in children. A few years ago, they made an important discovery: medulloblastoma can originate from one of two cell types: 1) stem cells, which can make all the different cell types in the brain or 2) neuronal progenitor cells, which can only make neurons.
Stem cells and progenitor cells are regulated by different growth factors. So, Wechsler-Reya thought, maybe the tumors arising from these cells respond differently to different therapies…
In a study published recently in the journal Oncogene, he and his team show that this is indeed the case. They looked at one growth factor in particular—basic fibroblast growth factor (bFGF)—and found that while it induces stem cell growth, it also inhibits neuronal progenitor cell growth.
What’s more, the researchers discovered that bFGF also blocks the growth of tumors that originate from progenitors. When they treated a mouse model of medulloblastoma with bFGF, it dramatically inhibited tumor growth.
Why do we get older? When do we die and why? Is there a life without ageing? For centuries, science has been fascinated by these questions. Now researchers from Kiel (Germany) have examined why the polyp Hydra is immortal – and unexpectedly discovered a link to ageing in humans. The study carried out by Kiel University together with the University Medical Center Schleswig-Holstein (UKSH) will be published this week in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). It was funded by the German Research Foundation DFG.
Extra chromosome 21 removed from Down syndrome cell line
University of Washington scientists have succeeded in removing the extra copy of chromosome 21 in cell cultures derived from a person with Down syndrome, a condition in which the body’s cells contain three copies of chromosome 21 rather than the usual pair.
A triplicate of any chromosome is a serious genetic abnormality called a trisomy. Trisomies account for almost one-quarter of pregnancy loss from spontaneous miscarriages, according to the research team. Besides Down syndrome (trisomy 21), some other human trisomies are extra Y or X chromosomes, and Edwards syndrome (trisomy 18) and Patau syndrome (trisomy 13), both of which have extremely high newborn fatality rates.
In their report appearing in the Nov. 2 edition of Cell Stem Cell, a team led by Dr. Li B. Li of the UW Department of Medicine described how they corrected trisomy 21 in human cell lines they grew in the lab. The senior scientists on the project were gene therapy researchers Dr. David W. Russell, professor of medicine and biochemistry, and Dr. Thalia Papayannopoulou, professor of medicine.
The targeted removal of a human trisomy, they noted, could have both clinical and research applications.
Computational Medicine Begins to Enhance the Way Doctors Detect and Treat Disease
Computational medicine, a fast-growing method of using computer models and sophisticated software to figure out how disease develops–and how to thwart it–has begun to leap off the drawing board and land in the hands of doctors who treat patients for heart ailments, cancer and other illnesses. Using digital tools, researchers have begun to use experimental and clinical data to build models that can unravel complex medical mysteries.
These are some of the conclusions of a new review of the field published in the Oct. 31 issue of the journal Science Translational Medicine. The article, “Computational Medicine: Translating Models to Clinical Care,” was written by four Johns Hopkins professors affiliated with the university’s Institute for Computational Medicine.
In recent years, “The field has exploded. There is a whole new community of people being trained in mathematics, computer science and engineering, and they are being cross-trained in biology,” said institute director Raimond Winslow. “This allows them to bring a whole new perspective to medical diagnosis and treatment. Engineers traditionally construct models of the systems they are designing. In our case, we’re building computational models of what we trying to study, which is disease.”
New MS drug proves effective where others have failed
A drug which ‘reboots’ a person’s immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a ‘first-line’ therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published today in the journal The Lancet.
The new studies, sponsored by Genzyme (a Sanofi company) and Bayer Schering Pharma, showed that alemtuzumab significantly reduces the number of attacks (or relapses) experienced by people with MS compared to interferon beta-1a (known commercially as Rebif). This was seen both in patients who had not previously received any treatment (drug-naïve) and those who have continued to show disease activity whilst taking an existing treatment for MS.
First micro-structure atlas of the human brain completed
A European team of scientists have built the first atlas of white-matter microstructure in the human brain. The project’s final results have the potential to change the face of neuroscience and medicine over the coming decade.
The work relied on groundbreaking MRI technology and was funded by the EU’s future and emerging technologies program with a grant of 2.4 million Euros. The participants of the project, called CONNECT, were drawn from leading research centers in countries across Europe including Israel, United Kingdom, Germany, France, Denmark, Switzerland and Italy.
The new atlas combines three-dimensional images from the MRI scans of 100 brains of volunteers. To achieve this, CONNECT developed advanced MRI methods providing unprecedented detail and accuracy.
Professor Daniel Alexander, a CONNECT steering committee member from the UCL Department of Computer Science said: “The UCL team use the latest computer modelling algorithms and hardware to invent new imaging techniques. The techniques we devised were key to realising the new CONNECT brain atlas.”The imaging techniques reveal new information about brain structure that help us understand how low-level cellular architecture relate to high-level thought processes.”
Why stem-cell science thrives in Japan
It’s easy to take for granted the epic scale of what some scientists are attempting these days. When the news broke a couple of weeks ago that Japanese scientists had turned normal cells from a mouse into eggs, and then fertilized them and seen them develop into baby mice, I thought it was pretty cool.
But I wasn’t that surprised.
I knew that Katsuhiko Hayashi — one of the scientists involved — was doing fascinating research on stem cells at Kyoto University, and so this seemed a natural progression for his work to take.
Then I spoke to him and his boss. What they said reminded me that they are attempting to do something that, until recently, would have blown the mind of almost any scientist, philosopher or other kind of intellectual there’s ever been throughout the whole of human history.
Mitinori Saitou, who is head of Hayashi’s lab at the Department of Anatomy and Cell Biology in the Graduate School of Medicine, was highly ambitious from an early age, and became particularly focused when he was doing his PhD as a young man.
"I got interested in germ-cell biology and the regulation of the cell fates," he told me, "hoping that one day it may be possible to develop a methodology to control cellular fate at will."
To control fate: It’s like something out of a Greek myth.
Med Sensation's Glove Tricorder is outfitted with numerous sensors to detect breast cancer and other internal medical problems when placed on different areas of the body.